Extracellular matrix synthetic pathways in dermal fibroblasts (ECM synthesis)

Extracellular matrix (ECM) synthetic pathways in dermal fibroblasts encompass the coordinated expression, post-translational modification, and secretion of structural proteins such as Type I and III collagen, elastin, and proteoglycans. These pathways are primarily governed by the Transforming Growth Factor-beta (TGF-beta) signaling axis, where ligand binding to TGF-beta receptors triggers Smad-mediated transcriptional activation of ECM genes (PubMed: 22507510). In physiological conditions, these processes are essential for maintaining skin elasticity, tensile strength, and effective wound healing. Pathological overactivation of these pathways leads to fibrotic diseases like systemic sclerosis and keloids, characterized by excessive collagen deposition and tissue hardening (PubMed: 24618210). Conversely, reduced activity in these pathways contributes to the thinning and fragility of aged skin. Therapeutic strategies often target these pathways using retinoids to stimulate synthesis or TGF-beta inhibitors to prevent pathological fibrosis (PubMed: 8630344). Because it encompasses a broad array of enzymes, structural proteins, and signaling molecules, it is considered a therapeutic area or pathway rather than a single discrete molecular target.

Other names

Dermal ECM productionFibroblast extracellular matrix synthesisCollagen biosynthetic pathwayDermal remodeling pathways

Modulation of the TGF-beta/Smad signaling pathway to regulate the transcription of genes encoding structural proteins like collagen and elastin, or inhibition of enzymes involved in ECM cross-linking and maturation.